A5040004427- Cutaneous Melanoma Detection and Management
- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- COVID-19 and healthcare impacts
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Cutaneous lymphoproliferative disorders research
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Poxvirus research and outbreaks
- Drug-Induced Adverse Reactions
- Lung Cancer Research Studies
- Acute Myeloid Leukemia Research
- Chemotherapy-related skin toxicity
- Colorectal Cancer Treatments and Studies
- Contact Dermatitis and Allergies
- Global Cancer Incidence and Screening
- Dermatological diseases and infestations
- RNA Interference and Gene Delivery
- Delphi Technique in Research
- Digital Imaging in Medicine
- Conferences and Exhibitions Management
- Optical Coherence Tomography Applications
- Autoimmune Bullous Skin Diseases
Memorial Sloan Kettering Cancer Center
2022-2025
Albany Medical Center Hospital
2021-2025
Brown University
2025
Kettering University
2022
Azienda Ospedaliero Universitaria San Giovanni Battista
2004
Prior malignancy exclusion criteria (PMEC) are often utilized in cancer clinical trials; however, the incidence of PMEC and association with trial participant age disparities remain poorly understood. This study aimed to identify oncologic randomized trials as a result PMEC. Using comprehensive collection modern phase III obtained via ClinicalTrials.gov, we assessed covariates associated excluding patients prior cancers within 5+ years from registration (PMEC-5). National Cancer Institute...
Abstract Background Pediatric central nervous system (CNS) tumors are the leading cause of pediatric cancer mortality. Research addressing genomic biomarkers and clinical outcomes is needed to inform therapeutic decision‐making. Methods We conducted a retrospective analysis patients (age <21) diagnosed with primary CNS tumor at four upstate New York hospitals from 2008 2021. Clinical histopathologic data were identified each patient, including somatic mutations mutational burden (TMB)...
Abstract BACKGROUND Selumetinib, a MEK inhibitor (MEKi), is approved for the treatment of plexiform neurofibromas (PN) in pediatric neurofibromatosis (NF) patients. In pivotal trials, nearly 70% participants had PN shrinkage; however, 93% experienced rash. This first study to characterize management trends MEKi induced dermatologic adverse events (DAEs). METHODS Physicians treating NF patients were surveyed assess DAE frequency, treatment, and effect on therapy. The survey was distributed...
Abstract BACKGROUND With the advent of immunotherapies and targeted therapies, research is needed to assess how pediatric brain tumor genomic biomarkers may impact treatment modality choice outcomes. METHODS We conducted a retrospective analysis 160 patients (78 male, 82 female) with median age 9 years (2 months-26 years) diagnosed primary CNS at four academic institutions from 2008-2023. Tumor mutational burden (TMB), type, outcomes, matching status were analyzed. Matching refers presence...
Background: The role of tumor genomics in influencing treatment outcomes remains a critical area investigation personalized medicine. This study is the first to evaluate relationship between mutational burden (TMB) and driver mutations (DM) pediatric brain tumors, examining their association with modalities patient outcomes. Methods: We conducted retrospective 160 patients (78 males, 82 females) median age 9 years (range: 2 months 26 years) who were diagnosed primary CNS tumors across four...
Abstract In pediatric central nervous system (CNS) tumors, high tumor mutational burden (TMB) (≥3 mutations/megabase (mut/Mb)) has been correlated with lower overall survival and higher rates of progression as compared to low TMB tumors (&lt;3 mut/Mb). This study is the first examine a subset CNS hypermutated (≥10 mut/Mb) in comparison tumors. We conducted retrospective analysis 121 patients (61 female (50%)) median age 9 years diagnosed primary (high TMB, N=34; N=55) at four academic...
Background: Earlier detection of melanoma leads to better outcomes and a more favorable prognosis.[1] There is relationship between anatomic location prognosis, but how visibility the lesion relates prognosis has not been studied.[2-5] We aimed determine if suspicious lesions by patients earlier diagnosis melanoma. conducted retrospective analysis 382 diagnosed with invasive at one institution 8/1/2018 11/1/2021. Visible were defined as occurring in locations visible patient, review physical...
Abstract Pediatric CNS tumors are the leading cause of pediatric cancer mortality. Research addressing genomic biomarkers and clinical outcomes is needed to inform therapeutic decision making. Tumor mutational burden (TMB) has been correlated with decreased survival across types. This study first examine TMB in tumor patients multiple academic medical centers. We conducted a retrospective analysis 121 (61 female (50%)) median age 9 diagnosed primary at Albany Medical Center, Roswell Park...